Moderna (MRNA) PT Raised to $43 at Oppenheimer; 'COVID-19 Vaccine Potential Taking Shape'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day
April 14, 2020 7:00 AM EDTVaccines create significant value for healthcare systems by preventing infectious disease; despite this, the vast majority of viruses do not have commercial vaccines available, representing a large opportunity
Moderna has demonstrated neutralizing immunogenicity against all eight viruses targeted in clinical trials to date using the Companys innovative vaccine platform
First interim analysis of Phase 1 Zika vaccine candidate (mRNA-1893) study shows that 10 µg and 30 µg dose levels seroconverted 94% and 100% of seronegative participants, respectively, and effectively boosted seropositive participants; both dose levels generally well-tolerated
NIH-led... More
